The Sunnyvale, Calif.-based company posted profits of $254.6 million, or $2.15 per share, on sales of $909.3 million for the three months ended June 30, for bottom-line growth of 14.2% on sales growth of 19.7% compared with the same period during the previous year.
Adjusted to exclude one-time items, earnings per share were $2.76, well ahead of the $2.50 consensus on Wall Street, where analysts expected to see sales of $877.6 million, which the company also topped.
“We are pleased with our customers’ increased use of da Vinci in the second quarter and the financial results that follow. We remain dedicated to working with our customers to deliver superior programs, while continuing to build on our record of innovation – including the recent clearances of our SP surgical system and 3rd generation stapling platform,” CEO Gary Guthart said in a press release.
Shares in Intuitive Surgical have risen approximately 4% in after-hours trading today, at $542 as of 4:48 p.m. EDT.
Earlier this month, Intuitive Surgical said that the FDA cleared its fully-wristed 60 mm stapler, SureForm 60.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.